X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
index medicus (38) 38
male (34) 34
female (32) 32
middle aged (29) 29
hematology (27) 27
adult (24) 24
aged (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
oncology (13) 13
prognosis (12) 12
treatment outcome (12) 12
disease-free survival (11) 11
survival (11) 11
transplantation, autologous (11) 11
adolescent (9) 9
aged, 80 and over (9) 9
remission induction (9) 9
chemotherapy (8) 8
cyclophosphamide - administration & dosage (8) 8
leukemia (8) 8
therapy (8) 8
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
disease (7) 7
high-dose therapy (7) 7
minimal residual disease (7) 7
multiple myeloma (7) 7
multiple myeloma - mortality (7) 7
survival analysis (7) 7
survival rate (7) 7
hematopoietic stem cell transplantation (6) 6
multivariate analysis (6) 6
stem-cell transplantation (6) 6
analysis (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
cyclophosphamide (5) 5
cyclophosphamide - adverse effects (5) 5
follow-up studies (5) 5
lymphoma (5) 5
mitoxantrone - administration & dosage (5) 5
multiple myeloma - therapy (5) 5
randomized-trial (5) 5
recurrence (5) 5
retrospective studies (5) 5
stem cell transplantation (5) 5
transplantation (5) 5
transplantation conditioning (5) 5
vidarabine - administration & dosage (5) 5
vidarabine - analogs & derivatives (5) 5
acute lymphoblastic leukemia (4) 4
antineoplastic agents - therapeutic use (4) 4
bone-marrow transplantation (4) 4
bone-marrow-transplantation (4) 4
bortezomib (4) 4
cell line, tumor (4) 4
children (4) 4
chromosome aberrations (4) 4
combined modality therapy (4) 4
cytogenetics (4) 4
doxorubicin - administration & dosage (4) 4
lymphomas (4) 4
methods (4) 4
multiple myeloma - drug therapy (4) 4
non-hodgkins-lymphoma (4) 4
phase-ii (4) 4
prednisone - administration & dosage (4) 4
prospective studies (4) 4
transplantation, homologous (4) 4
vidarabine - adverse effects (4) 4
vincristine - administration & dosage (4) 4
young adult (4) 4
adults (3) 3
age factors (3) 3
antineoplastic agents - adverse effects (3) 3
apoptosis (3) 3
autologous transplantation (3) 3
cancer (3) 3
cells (3) 3
child (3) 3
chronic lymphocytic-leukemia (3) 3
clinical trials (3) 3
complete remission (3) 3
doxorubicin (3) 3
elderly-patients (3) 3
genetic aspects (3) 3
immunofixation (3) 3
immunophenotyping (3) 3
induction chemotherapy (3) 3
lymphoma, follicular - drug therapy (3) 3
lymphoma, follicular - mortality (3) 3
melphalan - administration & dosage (3) 3
mitoxantrone - adverse effects (3) 3
multiple myeloma - surgery (3) 3
original research (3) 3
outcome (3) 3
patients (3) 3
peripheral blood stem cell transplantation (3) 3
pharmacology & pharmacy (3) 3
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (3) 3
proportional hazards models (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Haematologica, ISSN 0390-6078, 11/2010, Volume 95, Issue 11, pp. 1913 - 1920
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, pp. e0123978 - e0123978
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | SURVIVAL | PLUS DEXAMETHASONE | COMPLETE REMISSION | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Haematologica, ISSN 0390-6078, 04/2012, Volume 97, Issue 4, pp. 616 - 621
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2008, Volume 26, Issue 4, pp. 577 - 584
Journal Article
Blood, ISSN 0006-4971, 07/2011, Volume 118, Issue 3, pp. 529 - 534
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2013, Volume 163, Issue 5, pp. 581 - 589
Minimal residual disease monitoring is becoming increasingly important in multiple myeloma ( MM ), but multiparameter flow cytometry ( MFC ) and... 
flow cytometry | minimal residual disease | IGH | PCR | Multiple myeloma | fluorescent | Minimal residual disease | Flow cytometry | Fluorescent-PCR | LYMPHOPROLIFERATIONS | AUTOLOGOUS TRANSPLANTATION | REARRANGEMENTS | IMMUNOFIXATION | IMPACT | POLYMERASE-CHAIN-REACTION | THERAPY | fluorescent-PCR | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Prognosis | Multiple Myeloma - mortality | Humans | Middle Aged | Fluorometry - methods | Male | Transplantation, Autologous | Polymerase Chain Reaction - economics | Polymerase Chain Reaction - methods | Neoplasm, Residual | Multiple Myeloma - drug therapy | Clinical Trials, Phase III as Topic - statistics & numerical data | Diagnostic Tests, Routine - economics | Sensitivity and Specificity | Flow Cytometry - economics | Aged, 80 and over | Adult | Female | Gene Rearrangement, B-Lymphocyte, Light Chain | Multiple Myeloma - surgery | Multicenter Studies as Topic - statistics & numerical data | Hematopoietic Stem Cell Transplantation | Immunophenotyping | Genes, Immunoglobulin | Multiple Myeloma - pathology | Gene Rearrangement, B-Lymphocyte, Heavy Chain | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | DNA, Neoplasm - genetics | Fluorometry - economics | Multiple Myeloma - genetics | Genetic research | Immunoglobulins | Genetic aspects | Genes | Cancer | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2018, Volume 13, Issue 9, pp. e0203392 - e0203392
Journal Article
Haematologica, ISSN 0390-6078, 02/2012, Volume 97, Issue 2, pp. 310 - 317
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2015, Volume 92, Issue 1, pp. 84 - 90
Journal Article
Annals of Hematology, ISSN 0939-5555, 4/2017, Volume 96, Issue 4, pp. 639 - 646
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 03/2010, Volume 14, Issue 3, pp. 659 - 670
Journal Article